Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Alfiah, Noor"'
Autor:
Alfiah Noor, Gudrun Walser, Matthijs Wesseling, Philippe Giron, Albert-Menno Laffra, Fatima Haddouchi, Jacques De Grève, Peter Kronenberger
Publikováno v:
BMC Research Notes, Vol 11, Iss 1, Pp 1-7 (2018)
Abstract Objective Our aim was to produce a mono-biotinylated single domain antibody (‘nanobody’) specific for the epidermal growth factor receptor (EGFR), which is overexpressed in many cancer cells. The binding of the nanobody and its function
Externí odkaz:
https://doaj.org/article/41de9e26defe4117a52d47dfa64ff3d8
Autor:
Rajendra Bahadur Shahi, Hugo Vandenplas, Carolien Eggermont, Philippe Giron, Jacques De Greve, Erik Teugels, Bram Boeckx, Diether Lambrechts, Sylvia De Brakeleer, Alfiah Noor, Amir Noeparast
Publikováno v:
Oncogene
Two out of 41 non-small cell lung cancer patients enrolled in a clinical study were found with a somatic CRAF mutation in their tumor, namely CRAFP261A and CRAFP207S. To our knowledge, both mutations are novel in lung cancer and CRAFP261A has not bee
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b673b3b333a2060d3e558cfe0e11de1
https://doi.org/10.1038/s41388-019-0866-7
https://doi.org/10.1038/s41388-019-0866-7
Autor:
Gang Chen, Alfiah Noor, Peter Kronenberger, Erik Teugels, Ijeoma Adaku Umelo, Jacques De Grève
Publikováno v:
PLoS ONE, Vol 8, Iss 3, p e59708 (2013)
Epidermal growth factor receptor (EGFR) and c-MET receptors are expressed on many non-small cell lung cancer (NSCLC) cells. Current single agent therapeutic targeting of a mutant EGFR has a high efficacy in the clinic, but is not curative. Here, we i
Externí odkaz:
https://doaj.org/article/3ccdb423d083432cac895991f695483e
Autor:
Peter Kronenberger, Erik Teugels, Alfiah Noor, Ijeoma Adaku Umelo, Philippe Giron, Elly De Vlieghere, Jacques De Greve, Olivier De Wever
Publikováno v:
Oncotarget
ONCOTARGET
ONCOTARGET
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can selectively induce apoptosis in cancer cells without causing damage to normal cells. However, some tumors are resistant to TRAIL monotherapy and clinical studies assessing targeted a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3ae2a3253a75d3184cd9decf09a2400
http://europepmc.org/articles/PMC6033352
http://europepmc.org/articles/PMC6033352
Autor:
Matthijs Wesseling, Peter Kronenberger, Philippe Giron, Fatima Haddouchi, Gudrun Walser, Albert-Menno Laffra, Alfiah Noor, Jacques De Greve
Publikováno v:
BMC Research Notes, Vol 11, Iss 1, Pp 1-7 (2018)
BMC Research Notes
BMC Research Notes
Objective Our aim was to produce a mono-biotinylated single domain antibody (‘nanobody’) specific for the epidermal growth factor receptor (EGFR), which is overexpressed in many cancer cells. The binding of the nanobody and its function are teste
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a28cc7b45e1d96a6f1b0ce6e8709c919
https://doi.org/10.1186/s13104-018-3852-1
https://doi.org/10.1186/s13104-018-3852-1
Autor:
Alfiah Noor, Walser, Gudrun, Wesseling, Matthijs, Giron, Philippe, Albert-Menno Laffra, Haddouchi, Fatima, GrèVe, Jacques De, Kronenberger, Peter
Additional file 1. EL2B EcoRIâ HindIII insert in pET22b plasmid.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::171546dde7fbec7b9f1d767fb5dd9030
e14104 Background: TNF-related apoptosis-ligand (TRAIL) can selectively induce apoptosis in cancer cells without causing damage to normal cells. However, some tumors are resistant to TRAIL monotherapy and clinical studies assessing targeted agents to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a20722743ae63f63052c741f0dd4a84
https://doi.org/10.1200/jco.2017.35.15_suppl.e14104
https://doi.org/10.1200/jco.2017.35.15_suppl.e14104
Autor:
Gang Chen, Marc Bracke, Olivier De Wever, Erik Teugels, Ijeoma Adaku Umelo, Alfiah Noor, Peter Kronenberger, Jacques De Greve
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 90(2)
Introduction Lung cancer remains the leading cause of cancer-related mortality worldwide, with metastatic disease frequently a prominent feature at the time of diagnosis. The role of NSCLC-derived EGFR mutations in cancer cell proliferation and survi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c6faf1279a9f44a8a825623094f4ece
https://pubmed.ncbi.nlm.nih.gov/26342549
https://pubmed.ncbi.nlm.nih.gov/26342549
Autor:
Kshitiz Singh, Peter Kronenberger, Alfiah Noor, Olivier De Wever, Marc Bracke, Gang Chen, Ijeoma Adaku Umelo, Jan Van Deun, Jacques De Greve, Erik Teugels
Publikováno v:
Oncotarget
ONCOTARGET
ResearcherID
Vrije Universiteit Brussel
Europe PubMed Central
ONCOTARGET
ResearcherID
Vrije Universiteit Brussel
Europe PubMed Central
// Ijeoma Adaku Umelo 1 , Olivier De Wever 2 , Peter Kronenberger 1, 3 , Jan Van Deun 2 , Alfiah Noor 1 , Kshitiz Singh 4 , Erik Teugels 1 , Gang Chen 1 , Marc Bracke 2 , Jacques De Greve 1 1 Laboratory of Molecular Oncology and Department of Medical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::627f69838ed110b86f9ed08788f1bb63
https://pubmed.ncbi.nlm.nih.gov/25992771
https://pubmed.ncbi.nlm.nih.gov/25992771
Autor:
Jacques De Greve, Alfiah Noor, Gang Chen, Erik Teugels, Ijeoma Adaku Umelo, Peter Kronenberger
Publikováno v:
PLoS ONE, Vol 8, Iss 3, p e59708 (2013)
PLoS ONE
PLoS ONE
Epidermal growth factor receptor (EGFR) and c-MET receptors are expressed on many non-small cell lung cancer (NSCLC) cells. Current single agent therapeutic targeting of a mutant EGFR has a high efficacy in the clinic, but is not curative. Here, we i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0afe4e791f4869b7c3b83f94dbe3a5c
https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23527257/pdf/?tool=EBI
https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23527257/pdf/?tool=EBI